



GIG  
CYMRU  
NHS  
WALES

Bwrdd Iechyd Prifysgol  
Bae Abertawe  
Swansea Bay University  
Health Board

Cadeirydd/Chair: **Emma Woollett**  
Prif Weithredwr/Chief Executive: **Tracy Myhill**

**gofalu am ein gilydd, cydweithio, gwella bob amser**  
**caring for each other, working together, always improving**

Rydym yn croesawu gohebiaeth yn y Gymraeg ac yn y Saesneg. We welcome correspondence in Welsh or English.

Dyddiad/Date: 28<sup>th</sup> April 2020  
Ein Cyf / Our Ref: 20-D-008

☎ 01639 648363

✉ FOIA.Requests@wales.nhs.uk

[REDACTED]

Corporate Services  
Headquarters  
1 Talbot Gateway  
Baglan  
Port Talbot, SA12 7BR

[REDACTED]

I refer to your Freedom of Information Act Request acknowledged by ourselves on 15<sup>th</sup> April 2020. Your request sought information relating to prescribing data.

**Within your health board how many patients are currently (within the past 3 months) being treated with the following regardless of patient diagnosis**

**Abemaciclib + aromatase inhibitor** - 9 in total (may be in combination as not separated on our systems)

**Abemaciclib + Fulvestrant** - As above

**Alpelisib + Fulvestrant** - Nil

**Atezolizumab** - 9

**Avelumab** - Nil

**Bevacizumab** - 9

**Eribulin** - <5

**Everolimus + Exemestane** - 5 for Everolimus single agent, Exemestane is not prescribed on our systems.

**Fulvestrant as a single agent** - 18 in total (may be in combination as not separated on our systems)

**Gemcitabine + paclitaxel** - Nil

**Herceptin IV** - Nil



Pencadlys BIP Bae Abertawe, Un Porthfa Talbot, Port Talbot, SA12 7BR / Swansea Bay UHB Headquarters, One Talbot Gateway, Port Talbot, SA12 7BR

Bwrdd Iechyd Prifysgol Bae Abertawe yw enw gweithredu Bwrdd Iechyd Lleol Prifysgol Bae Abertawe  
Swansea Bay University Health Board is the operational name of Swansea Bay University Local Health Board

**Herceptin SC** - 68

**Lapatinib** - Nil

**Neratinib** - <5

**Nivolumab** - 31

**Olaparib** - Nil

**Palbociclib + aromatase inhibitor** - 41 in total (may be in combination as not separated on our systems)

**Pembrolizumab** - 14

**Pertuzumab + trastuzumab + docetaxel** - 36

**Ribociclib + aromatase inhibitor** - <5 in total (may be in combination as not separated on our systems)

**Ribociclib + Fulvestrant** - As above

**Talazoparib** - Nil

**Trastuzumab biosimilar IV** - 6

**Trastuzumab biosimilar SC** - Nil

**Trastuzumab emtansine** - <5

Where fewer than 5 has been indicated we are unable to provide you with the exact number of patients as due to the low numbers, there is a potential risk of identifying individuals if this was disclosed. We are therefore withholding this detail under Section 40(2) of the Freedom of Information Act 2000. This information is protected by the General Data Protection Regulation (GDPR) and Data Protection Act 2018 and its disclosure would be contrary to the data protection principles and constitute as unfair and unlawful processing in regard to Articles 5, 6, and 9 of GDPR. This exemption is absolute and therefore there is no requirement to apply the public interest test.

I hope this information is helpful. If you require anything further please contact us at [FOIA.Requests@wales.nhs.uk](mailto:FOIA.Requests@wales.nhs.uk).

Under the terms of the Health Board's Freedom of Information policy, individuals seeking access to recorded information held by the Health Board are entitled to request internal review of the handling of their requests. If you would like to complain about the Health Board's handling of your request please contact me directly at the address below or register your complaint via [FOIA.Requests@wales.nhs.uk](mailto:FOIA.Requests@wales.nhs.uk).

If after Internal Review you remain dissatisfied you are also entitled to refer the matter to the information commissioner at the Information Commissioner's Office (Wales), 2<sup>nd</sup> Floor, Churchill House, Churchill Way, Cardiff, CF10 2HH. Telephone Number: 029 2067 8400.

Yours sincerely



P. a. wenger

Pam Wenger  
**Director of Corporate Governance**

